nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Electrocardiogram QT corrected interval prolonged—Vemurafenib—melanoma	0.0438	0.0625	CcSEcCtD
Regadenoson—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.0184	0.0262	CcSEcCtD
Regadenoson—Adenosine triphosphate—APAF1—melanoma	0.018	0.758	CrCbGaD
Regadenoson—Haemorrhage intracranial—Temozolomide—melanoma	0.0147	0.021	CcSEcCtD
Regadenoson—Altered state of consciousness—Temozolomide—melanoma	0.013	0.0186	CcSEcCtD
Regadenoson—Faecal incontinence—Carmustine—melanoma	0.0123	0.0176	CcSEcCtD
Regadenoson—Transient ischaemic attack—Temozolomide—melanoma	0.0119	0.017	CcSEcCtD
Regadenoson—Faecal incontinence—Temozolomide—melanoma	0.0119	0.017	CcSEcCtD
Regadenoson—Musculoskeletal pain—Vemurafenib—melanoma	0.0119	0.017	CcSEcCtD
Regadenoson—Atrial flutter—Docetaxel—melanoma	0.0105	0.015	CcSEcCtD
Regadenoson—Atrial fibrillation—Vemurafenib—melanoma	0.00903	0.0129	CcSEcCtD
Regadenoson—Pain in extremity—Vemurafenib—melanoma	0.00855	0.0122	CcSEcCtD
Regadenoson—Injection site pain—Carmustine—melanoma	0.00763	0.0109	CcSEcCtD
Regadenoson—Wheezing—Bleomycin—melanoma	0.00693	0.0099	CcSEcCtD
Regadenoson—Musculoskeletal pain—Temozolomide—melanoma	0.0061	0.0087	CcSEcCtD
Regadenoson—Depressed level of consciousness—Carmustine—melanoma	0.00602	0.00859	CcSEcCtD
Regadenoson—Depressed level of consciousness—Temozolomide—melanoma	0.00582	0.0083	CcSEcCtD
Regadenoson—Connective tissue disorder—Vemurafenib—melanoma	0.00582	0.0083	CcSEcCtD
Regadenoson—Eye disorder—Vemurafenib—melanoma	0.00553	0.0079	CcSEcCtD
Regadenoson—Cardiac disorder—Vemurafenib—melanoma	0.00549	0.00784	CcSEcCtD
Regadenoson—Angiopathy—Vemurafenib—melanoma	0.00537	0.00767	CcSEcCtD
Regadenoson—Mediastinal disorder—Vemurafenib—melanoma	0.00533	0.00762	CcSEcCtD
Regadenoson—Cerebrovascular accident—Bleomycin—melanoma	0.00529	0.00755	CcSEcCtD
Regadenoson—Erythema—Vemurafenib—melanoma	0.00515	0.00736	CcSEcCtD
Regadenoson—Dysgeusia—Vemurafenib—melanoma	0.00504	0.0072	CcSEcCtD
Regadenoson—Eye pain—Carmustine—melanoma	0.00501	0.00716	CcSEcCtD
Regadenoson—Myocardial ischaemia—Docetaxel—melanoma	0.00498	0.00711	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—melanoma	0.00488	0.206	CrCbGaD
Regadenoson—Eye pain—Temozolomide—melanoma	0.00484	0.00691	CcSEcCtD
Regadenoson—Chest discomfort—Docetaxel—melanoma	0.00453	0.00646	CcSEcCtD
Regadenoson—Cough—Vemurafenib—melanoma	0.0045	0.00642	CcSEcCtD
Regadenoson—Bronchospasm—Bleomycin—melanoma	0.00441	0.00629	CcSEcCtD
Regadenoson—Myalgia—Vemurafenib—melanoma	0.00439	0.00626	CcSEcCtD
Regadenoson—Arthralgia—Vemurafenib—melanoma	0.00439	0.00626	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00436	0.00622	CcSEcCtD
Regadenoson—Anaphylactic shock—Vemurafenib—melanoma	0.0042	0.006	CcSEcCtD
Regadenoson—Nervous system disorder—Vemurafenib—melanoma	0.00412	0.00589	CcSEcCtD
Regadenoson—Skin disorder—Vemurafenib—melanoma	0.00408	0.00583	CcSEcCtD
Regadenoson—Acute coronary syndrome—Bleomycin—melanoma	0.00394	0.00562	CcSEcCtD
Regadenoson—Hypotension—Vemurafenib—melanoma	0.00393	0.00561	CcSEcCtD
Regadenoson—Myocardial infarction—Bleomycin—melanoma	0.00392	0.00559	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00383	0.00547	CcSEcCtD
Regadenoson—Abdominal distension—Temozolomide—melanoma	0.0038	0.00543	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vemurafenib—melanoma	0.00363	0.00518	CcSEcCtD
Regadenoson—Hypoaesthesia—Bleomycin—melanoma	0.00357	0.00509	CcSEcCtD
Regadenoson—Renal failure—Carmustine—melanoma	0.00343	0.00489	CcSEcCtD
Regadenoson—Flushing—Bleomycin—melanoma	0.00333	0.00475	CcSEcCtD
Regadenoson—Erythema—Bleomycin—melanoma	0.00312	0.00446	CcSEcCtD
Regadenoson—Hypoaesthesia—Carmustine—melanoma	0.00311	0.00445	CcSEcCtD
Regadenoson—Flushing—Dactinomycin—melanoma	0.0031	0.00443	CcSEcCtD
Regadenoson—Hypersensitivity—Vemurafenib—melanoma	0.0031	0.00442	CcSEcCtD
Regadenoson—Connective tissue disorder—Carmustine—melanoma	0.00308	0.00439	CcSEcCtD
Regadenoson—Atrial fibrillation—Docetaxel—melanoma	0.00307	0.00438	CcSEcCtD
Regadenoson—Renal impairment—Docetaxel—melanoma	0.00305	0.00436	CcSEcCtD
Regadenoson—Asthenia—Vemurafenib—melanoma	0.00302	0.00431	CcSEcCtD
Regadenoson—Hypoaesthesia—Temozolomide—melanoma	0.00301	0.0043	CcSEcCtD
Regadenoson—Connective tissue disorder—Temozolomide—melanoma	0.00297	0.00424	CcSEcCtD
Regadenoson—Eye disorder—Carmustine—melanoma	0.00292	0.00418	CcSEcCtD
Regadenoson—Erythema—Dactinomycin—melanoma	0.00291	0.00416	CcSEcCtD
Regadenoson—Pain in extremity—Docetaxel—melanoma	0.00291	0.00415	CcSEcCtD
Regadenoson—Flushing—Carmustine—melanoma	0.0029	0.00415	CcSEcCtD
Regadenoson—Ill-defined disorder—Bleomycin—melanoma	0.0029	0.00414	CcSEcCtD
Regadenoson—Diarrhoea—Vemurafenib—melanoma	0.00288	0.00411	CcSEcCtD
Regadenoson—Eye disorder—Temozolomide—melanoma	0.00283	0.00404	CcSEcCtD
Regadenoson—Tinnitus—Temozolomide—melanoma	0.00282	0.00403	CcSEcCtD
Regadenoson—Malaise—Bleomycin—melanoma	0.00281	0.00402	CcSEcCtD
Regadenoson—Cardiac disorder—Temozolomide—melanoma	0.00281	0.00401	CcSEcCtD
Regadenoson—Flushing—Temozolomide—melanoma	0.00281	0.00401	CcSEcCtD
Regadenoson—Dizziness—Vemurafenib—melanoma	0.00278	0.00397	CcSEcCtD
Regadenoson—Angiopathy—Temozolomide—melanoma	0.00274	0.00392	CcSEcCtD
Regadenoson—Mental disorder—Carmustine—melanoma	0.00274	0.00392	CcSEcCtD
Regadenoson—Immune system disorder—Temozolomide—melanoma	0.00273	0.0039	CcSEcCtD
Regadenoson—Mediastinal disorder—Temozolomide—melanoma	0.00273	0.00389	CcSEcCtD
Regadenoson—Erythema—Carmustine—melanoma	0.00272	0.00389	CcSEcCtD
Regadenoson—Cough—Bleomycin—melanoma	0.00272	0.00389	CcSEcCtD
Regadenoson—Ill-defined disorder—Dactinomycin—melanoma	0.0027	0.00386	CcSEcCtD
Regadenoson—Vomiting—Vemurafenib—melanoma	0.00267	0.00382	CcSEcCtD
Regadenoson—Chest pain—Bleomycin—melanoma	0.00266	0.00379	CcSEcCtD
Regadenoson—Myalgia—Bleomycin—melanoma	0.00266	0.00379	CcSEcCtD
Regadenoson—Rash—Vemurafenib—melanoma	0.00265	0.00379	CcSEcCtD
Regadenoson—Mental disorder—Temozolomide—melanoma	0.00265	0.00378	CcSEcCtD
Regadenoson—Dermatitis—Vemurafenib—melanoma	0.00265	0.00378	CcSEcCtD
Regadenoson—Headache—Vemurafenib—melanoma	0.00263	0.00376	CcSEcCtD
Regadenoson—Erythema—Temozolomide—melanoma	0.00263	0.00376	CcSEcCtD
Regadenoson—Discomfort—Bleomycin—melanoma	0.00263	0.00375	CcSEcCtD
Regadenoson—Malaise—Dactinomycin—melanoma	0.00263	0.00375	CcSEcCtD
Regadenoson—Dysgeusia—Temozolomide—melanoma	0.00258	0.00368	CcSEcCtD
Regadenoson—Vision blurred—Carmustine—melanoma	0.00257	0.00367	CcSEcCtD
Regadenoson—Tremor—Carmustine—melanoma	0.00255	0.00364	CcSEcCtD
Regadenoson—Anaphylactic shock—Bleomycin—melanoma	0.00255	0.00364	CcSEcCtD
Regadenoson—Nausea—Vemurafenib—melanoma	0.0025	0.00357	CcSEcCtD
Regadenoson—Vision blurred—Temozolomide—melanoma	0.00248	0.00354	CcSEcCtD
Regadenoson—Myalgia—Dactinomycin—melanoma	0.00248	0.00354	CcSEcCtD
Regadenoson—Bronchospasm—Docetaxel—melanoma	0.00247	0.00353	CcSEcCtD
Regadenoson—Tremor—Temozolomide—melanoma	0.00247	0.00352	CcSEcCtD
Regadenoson—Discomfort—Dactinomycin—melanoma	0.00245	0.0035	CcSEcCtD
Regadenoson—Angina pectoris—Docetaxel—melanoma	0.00245	0.0035	CcSEcCtD
Regadenoson—Ill-defined disorder—Temozolomide—melanoma	0.00244	0.00349	CcSEcCtD
Regadenoson—Angioedema—Temozolomide—melanoma	0.00241	0.00344	CcSEcCtD
Regadenoson—Hypotension—Bleomycin—melanoma	0.00238	0.0034	CcSEcCtD
Regadenoson—Malaise—Temozolomide—melanoma	0.00237	0.00339	CcSEcCtD
Regadenoson—Convulsion—Carmustine—melanoma	0.00236	0.00337	CcSEcCtD
Regadenoson—Hypertension—Carmustine—melanoma	0.00235	0.00336	CcSEcCtD
Regadenoson—Palpitations—Temozolomide—melanoma	0.00233	0.00332	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Bleomycin—melanoma	0.00232	0.00331	CcSEcCtD
Regadenoson—Chest pain—Carmustine—melanoma	0.00232	0.00331	CcSEcCtD
Regadenoson—Myalgia—Carmustine—melanoma	0.00232	0.00331	CcSEcCtD
Regadenoson—Anxiety—Carmustine—melanoma	0.00231	0.0033	CcSEcCtD
Regadenoson—Cough—Temozolomide—melanoma	0.0023	0.00328	CcSEcCtD
Regadenoson—Paraesthesia—Bleomycin—melanoma	0.00229	0.00327	CcSEcCtD
Regadenoson—Convulsion—Temozolomide—melanoma	0.00228	0.00326	CcSEcCtD
Regadenoson—Hypertension—Temozolomide—melanoma	0.00227	0.00325	CcSEcCtD
Regadenoson—Dyspnoea—Bleomycin—melanoma	0.00227	0.00324	CcSEcCtD
Regadenoson—Myalgia—Temozolomide—melanoma	0.00224	0.0032	CcSEcCtD
Regadenoson—Arthralgia—Temozolomide—melanoma	0.00224	0.0032	CcSEcCtD
Regadenoson—Anxiety—Temozolomide—melanoma	0.00223	0.00319	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00223	0.00318	CcSEcCtD
Regadenoson—Discomfort—Temozolomide—melanoma	0.00221	0.00316	CcSEcCtD
Regadenoson—Acute coronary syndrome—Docetaxel—melanoma	0.00221	0.00315	CcSEcCtD
Regadenoson—Renal failure—Docetaxel—melanoma	0.0022	0.00314	CcSEcCtD
Regadenoson—Myocardial infarction—Docetaxel—melanoma	0.0022	0.00314	CcSEcCtD
Regadenoson—Pain—Bleomycin—melanoma	0.00218	0.00311	CcSEcCtD
Regadenoson—Tachycardia—Carmustine—melanoma	0.00217	0.0031	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00216	0.00309	CcSEcCtD
Regadenoson—Anaphylactic shock—Temozolomide—melanoma	0.00215	0.00307	CcSEcCtD
Regadenoson—Nervous system disorder—Temozolomide—melanoma	0.00211	0.00301	CcSEcCtD
Regadenoson—Feeling abnormal—Bleomycin—melanoma	0.0021	0.003	CcSEcCtD
Regadenoson—Skin disorder—Temozolomide—melanoma	0.00209	0.00298	CcSEcCtD
Regadenoson—Hypotension—Carmustine—melanoma	0.00208	0.00297	CcSEcCtD
Regadenoson—Hyperhidrosis—Temozolomide—melanoma	0.00208	0.00297	CcSEcCtD
Regadenoson—Pain—Dactinomycin—melanoma	0.00203	0.0029	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Carmustine—melanoma	0.00203	0.00289	CcSEcCtD
Regadenoson—Urticaria—Bleomycin—melanoma	0.00202	0.00289	CcSEcCtD
Regadenoson—Insomnia—Carmustine—melanoma	0.00201	0.00287	CcSEcCtD
Regadenoson—Hypoaesthesia—Docetaxel—melanoma	0.002	0.00286	CcSEcCtD
Regadenoson—Paraesthesia—Carmustine—melanoma	0.002	0.00285	CcSEcCtD
Regadenoson—Dyspnoea—Carmustine—melanoma	0.00198	0.00283	CcSEcCtD
Regadenoson—Somnolence—Carmustine—melanoma	0.00198	0.00282	CcSEcCtD
Regadenoson—Connective tissue disorder—Docetaxel—melanoma	0.00198	0.00282	CcSEcCtD
Regadenoson—Feeling abnormal—Dactinomycin—melanoma	0.00196	0.0028	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Temozolomide—melanoma	0.00196	0.0028	CcSEcCtD
Regadenoson—Insomnia—Temozolomide—melanoma	0.00194	0.00277	CcSEcCtD
Regadenoson—Gastrointestinal pain—Dactinomycin—melanoma	0.00194	0.00277	CcSEcCtD
Regadenoson—Paraesthesia—Temozolomide—melanoma	0.00193	0.00275	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Carmustine—melanoma	0.00192	0.00274	CcSEcCtD
Regadenoson—Dyspnoea—Temozolomide—melanoma	0.00192	0.00274	CcSEcCtD
Regadenoson—Somnolence—Temozolomide—melanoma	0.00191	0.00273	CcSEcCtD
Regadenoson—Pain—Carmustine—melanoma	0.0019	0.00271	CcSEcCtD
Regadenoson—Eye disorder—Docetaxel—melanoma	0.00188	0.00268	CcSEcCtD
Regadenoson—Abdominal pain—Dactinomycin—melanoma	0.00188	0.00268	CcSEcCtD
Regadenoson—Hypersensitivity—Bleomycin—melanoma	0.00188	0.00268	CcSEcCtD
Regadenoson—Flushing—Docetaxel—melanoma	0.00187	0.00267	CcSEcCtD
Regadenoson—Cardiac disorder—Docetaxel—melanoma	0.00187	0.00267	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Temozolomide—melanoma	0.00186	0.00265	CcSEcCtD
Regadenoson—Pain—Temozolomide—melanoma	0.00184	0.00262	CcSEcCtD
Regadenoson—Feeling abnormal—Carmustine—melanoma	0.00183	0.00262	CcSEcCtD
Regadenoson—Asthenia—Bleomycin—melanoma	0.00183	0.00261	CcSEcCtD
Regadenoson—Angiopathy—Docetaxel—melanoma	0.00182	0.00261	CcSEcCtD
Regadenoson—Gastrointestinal pain—Carmustine—melanoma	0.00182	0.0026	CcSEcCtD
Regadenoson—Immune system disorder—Docetaxel—melanoma	0.00182	0.00259	CcSEcCtD
Regadenoson—Mediastinal disorder—Docetaxel—melanoma	0.00181	0.00259	CcSEcCtD
Regadenoson—Feeling abnormal—Temozolomide—melanoma	0.00177	0.00253	CcSEcCtD
Regadenoson—Mental disorder—Docetaxel—melanoma	0.00176	0.00252	CcSEcCtD
Regadenoson—Abdominal pain—Carmustine—melanoma	0.00176	0.00251	CcSEcCtD
Regadenoson—Gastrointestinal pain—Temozolomide—melanoma	0.00176	0.00251	CcSEcCtD
Regadenoson—Erythema—Docetaxel—melanoma	0.00175	0.0025	CcSEcCtD
Regadenoson—Hypersensitivity—Dactinomycin—melanoma	0.00175	0.0025	CcSEcCtD
Regadenoson—Dysgeusia—Docetaxel—melanoma	0.00171	0.00245	CcSEcCtD
Regadenoson—Urticaria—Temozolomide—melanoma	0.00171	0.00244	CcSEcCtD
Regadenoson—Asthenia—Dactinomycin—melanoma	0.0017	0.00243	CcSEcCtD
Regadenoson—Abdominal pain—Temozolomide—melanoma	0.0017	0.00243	CcSEcCtD
Regadenoson—Hypersensitivity—Carmustine—melanoma	0.00164	0.00234	CcSEcCtD
Regadenoson—Diarrhoea—Dactinomycin—melanoma	0.00163	0.00232	CcSEcCtD
Regadenoson—Vomiting—Bleomycin—melanoma	0.00162	0.00231	CcSEcCtD
Regadenoson—Rash—Bleomycin—melanoma	0.00161	0.00229	CcSEcCtD
Regadenoson—Dermatitis—Bleomycin—melanoma	0.0016	0.00229	CcSEcCtD
Regadenoson—Asthenia—Carmustine—melanoma	0.0016	0.00228	CcSEcCtD
Regadenoson—Hypersensitivity—Temozolomide—melanoma	0.00158	0.00226	CcSEcCtD
Regadenoson—Syncope—Docetaxel—melanoma	0.00157	0.00224	CcSEcCtD
Regadenoson—Palpitations—Docetaxel—melanoma	0.00155	0.00221	CcSEcCtD
Regadenoson—Asthenia—Temozolomide—melanoma	0.00154	0.0022	CcSEcCtD
Regadenoson—Loss of consciousness—Docetaxel—melanoma	0.00154	0.0022	CcSEcCtD
Regadenoson—Cough—Docetaxel—melanoma	0.00153	0.00218	CcSEcCtD
Regadenoson—Diarrhoea—Carmustine—melanoma	0.00152	0.00217	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—melanoma	0.00152	0.00217	CcSEcCtD
Regadenoson—Nausea—Bleomycin—melanoma	0.00151	0.00216	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—melanoma	0.00151	0.00216	CcSEcCtD
Regadenoson—Vomiting—Dactinomycin—melanoma	0.00151	0.00216	CcSEcCtD
Regadenoson—Rash—Dactinomycin—melanoma	0.0015	0.00214	CcSEcCtD
Regadenoson—Myalgia—Docetaxel—melanoma	0.00149	0.00213	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—melanoma	0.00149	0.00213	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—melanoma	0.00149	0.00213	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00148	0.00211	CcSEcCtD
Regadenoson—Dizziness—Carmustine—melanoma	0.00147	0.0021	CcSEcCtD
Regadenoson—Diarrhoea—Temozolomide—melanoma	0.00147	0.0021	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—melanoma	0.00143	0.00204	CcSEcCtD
Regadenoson—Dizziness—Temozolomide—melanoma	0.00142	0.00203	CcSEcCtD
Regadenoson—Vomiting—Carmustine—melanoma	0.00141	0.00202	CcSEcCtD
Regadenoson—Nausea—Dactinomycin—melanoma	0.00141	0.00201	CcSEcCtD
Regadenoson—Shock—Docetaxel—melanoma	0.00141	0.00201	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—TAS2R60—melanoma	0.00141	0.00509	CbGpPWpGaD
Regadenoson—Rash—Carmustine—melanoma	0.0014	0.002	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—melanoma	0.0014	0.002	CcSEcCtD
Regadenoson—Dermatitis—Carmustine—melanoma	0.0014	0.002	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—melanoma	0.00139	0.00199	CcSEcCtD
Regadenoson—Headache—Carmustine—melanoma	0.00139	0.00199	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—melanoma	0.00139	0.00198	CcSEcCtD
Regadenoson—Vomiting—Temozolomide—melanoma	0.00137	0.00195	CcSEcCtD
Regadenoson—Rash—Temozolomide—melanoma	0.00135	0.00193	CcSEcCtD
Regadenoson—Dermatitis—Temozolomide—melanoma	0.00135	0.00193	CcSEcCtD
Regadenoson—Headache—Temozolomide—melanoma	0.00135	0.00192	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CXCR4—melanoma	0.00134	0.00484	CbGpPWpGaD
Regadenoson—Hypotension—Docetaxel—melanoma	0.00134	0.00191	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00133	0.00482	CbGpPWpGaD
Regadenoson—Nausea—Carmustine—melanoma	0.00132	0.00189	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—melanoma	0.0013	0.00186	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—melanoma	0.00129	0.00185	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB4—melanoma	0.00129	0.00467	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.00129	0.00467	CbGpPWpGaD
Regadenoson—Paraesthesia—Docetaxel—melanoma	0.00128	0.00183	CcSEcCtD
Regadenoson—Nausea—Temozolomide—melanoma	0.00128	0.00182	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—melanoma	0.00127	0.00182	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—melanoma	0.00127	0.00181	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD86—melanoma	0.00124	0.00448	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Docetaxel—melanoma	0.00123	0.00176	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FOXO4—melanoma	0.00123	0.00446	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HDAC2—melanoma	0.00123	0.00446	CbGpPWpGaD
Regadenoson—Pain—Docetaxel—melanoma	0.00122	0.00174	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF1—melanoma	0.0012	0.00434	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCR2—melanoma	0.00119	0.00432	CbGpPWpGaD
Regadenoson—Feeling abnormal—Docetaxel—melanoma	0.00118	0.00168	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—PLCB4—melanoma	0.00117	0.00425	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL1—melanoma	0.00117	0.00425	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Docetaxel—melanoma	0.00117	0.00167	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PDGFRA—melanoma	0.00116	0.00421	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—WNT5A—melanoma	0.00115	0.00418	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PRKCA—melanoma	0.00115	0.00416	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00114	0.00415	CbGpPWpGaD
Regadenoson—Abdominal pain—Docetaxel—melanoma	0.00113	0.00161	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAP2K2—melanoma	0.00112	0.00407	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT3—melanoma	0.00112	0.00407	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NGFR—melanoma	0.00112	0.00407	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—FAS—melanoma	0.00111	0.00402	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL1—melanoma	0.00106	0.00386	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PLCB4—melanoma	0.00106	0.00386	CbGpPWpGaD
Regadenoson—Hypersensitivity—Docetaxel—melanoma	0.00105	0.0015	CcSEcCtD
Regadenoson—Asthenia—Docetaxel—melanoma	0.00103	0.00146	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—F2R—melanoma	0.00101	0.00367	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2RL1—melanoma	0.000997	0.00361	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB4—melanoma	0.000992	0.00359	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—EDNRB—melanoma	0.000982	0.00356	CbGpPWpGaD
Regadenoson—Diarrhoea—Docetaxel—melanoma	0.000978	0.0014	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—DRAP1—melanoma	0.000976	0.00354	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYO7A—melanoma	0.000976	0.00354	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—CDK4—melanoma	0.000975	0.00353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CD86—melanoma	0.000951	0.00344	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NOS2—melanoma	0.000948	0.00343	CbGpPWpGaD
Regadenoson—Dizziness—Docetaxel—melanoma	0.000945	0.00135	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM3—melanoma	0.000938	0.0034	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGF1—melanoma	0.000922	0.00334	CbGpPWpGaD
Regadenoson—Vomiting—Docetaxel—melanoma	0.000909	0.0013	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—F2RL1—melanoma	0.000906	0.00328	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CD80—melanoma	0.000902	0.00327	CbGpPWpGaD
Regadenoson—Rash—Docetaxel—melanoma	0.000901	0.00129	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—melanoma	0.0009	0.00129	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—melanoma	0.0009	0.00326	CbGpPWpGaD
Regadenoson—Headache—Docetaxel—melanoma	0.000895	0.00128	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PDGFRA—melanoma	0.000893	0.00324	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGF—melanoma	0.00089	0.00322	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—KISS1—melanoma	0.000889	0.00322	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PPARG—melanoma	0.000886	0.00321	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PRKCA—melanoma	0.000884	0.0032	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.000877	0.00318	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCR4—melanoma	0.000872	0.00316	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAP2K2—melanoma	0.000864	0.00313	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR1—melanoma	0.000861	0.00312	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCB1—melanoma	0.000852	0.036	CrCbGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM3—melanoma	0.000851	0.00309	CbGpPWpGaD
Regadenoson—Nausea—Docetaxel—melanoma	0.000849	0.00121	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—MC1R—melanoma	0.000848	0.00307	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—melanoma	0.000846	0.00307	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TAS2R60—melanoma	0.00083	0.00301	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RAC1—melanoma	0.000819	0.00297	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM1—melanoma	0.000813	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR7—melanoma	0.000813	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KISS1—melanoma	0.000807	0.00292	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAP2K1—melanoma	0.000796	0.00289	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—melanoma	0.000791	0.00287	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR1—melanoma	0.000782	0.00283	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MC1R—melanoma	0.00077	0.00279	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF2—melanoma	0.000758	0.00275	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RHOB—melanoma	0.00074	0.00268	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM1—melanoma	0.000738	0.00268	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR7—melanoma	0.000738	0.00268	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—melanoma	0.000709	0.00257	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—melanoma	0.000699	0.00253	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CD80—melanoma	0.000693	0.00251	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KIT—melanoma	0.000692	0.00251	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—melanoma	0.00069	0.0025	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGF—melanoma	0.000684	0.00248	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR2—melanoma	0.000674	0.00244	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RHOB—melanoma	0.000672	0.00243	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—EDN1—melanoma	0.000668	0.00242	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RAC2—melanoma	0.000663	0.0024	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—melanoma	0.000651	0.00236	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—melanoma	0.000647	0.00235	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL1—melanoma	0.000629	0.00228	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLCB4—melanoma	0.000629	0.00228	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAP2K1—melanoma	0.000613	0.00222	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR2—melanoma	0.000612	0.00222	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—melanoma	0.000609	0.00221	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—melanoma	0.000608	0.0022	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAC2—melanoma	0.000602	0.00218	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—melanoma	0.000597	0.00216	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—melanoma	0.000596	0.00216	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—WNT5A—melanoma	0.000592	0.00215	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TRRAP—melanoma	0.000592	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CUL3—melanoma	0.000592	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGF2—melanoma	0.000583	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1B10—melanoma	0.000575	0.00209	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—F2R—melanoma	0.000573	0.00208	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDNRB—melanoma	0.000555	0.00201	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—melanoma	0.000545	0.00198	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—melanoma	0.000537	0.00195	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2RL1—melanoma	0.000535	0.00194	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—melanoma	0.000533	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—melanoma	0.000532	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—melanoma	0.00053	0.00192	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNA11—melanoma	0.000524	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GAB2—melanoma	0.000524	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—F2R—melanoma	0.00052	0.00188	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—melanoma	0.000509	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDNRB—melanoma	0.000504	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM3—melanoma	0.000503	0.00182	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1B—melanoma	0.000498	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCR4—melanoma	0.000493	0.00178	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—melanoma	0.000488	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNAQ—melanoma	0.000487	0.00176	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK1—melanoma	0.000484	0.00176	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—melanoma	0.000484	0.00176	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KISS1—melanoma	0.000477	0.00173	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GAB2—melanoma	0.000476	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNA11—melanoma	0.000476	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000474	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SKI—melanoma	0.000462	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR1—melanoma	0.000462	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—melanoma	0.000459	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—melanoma	0.000458	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—melanoma	0.000458	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NFKB1—melanoma	0.000456	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MC1R—melanoma	0.000455	0.00165	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT3—melanoma	0.000449	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCR4—melanoma	0.000447	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNAQ—melanoma	0.000442	0.0016	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR7—melanoma	0.000436	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM1—melanoma	0.000436	0.00158	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SUFU—melanoma	0.000425	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—melanoma	0.00042	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—melanoma	0.000415	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—melanoma	0.00041	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NRAS—melanoma	0.000409	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT3—melanoma	0.000408	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RHOB—melanoma	0.000397	0.00144	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BCL2L11—melanoma	0.000397	0.00144	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—melanoma	0.000392	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—melanoma	0.000389	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC6—melanoma	0.000381	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—melanoma	0.00038	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—EDN1—melanoma	0.000378	0.00137	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK1—melanoma	0.000373	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—melanoma	0.000373	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—melanoma	0.000372	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CSF2—melanoma	0.000369	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR2—melanoma	0.000361	0.00131	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—melanoma	0.000361	0.00131	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAC2—melanoma	0.000355	0.00129	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCA—melanoma	0.000354	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—melanoma	0.000352	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFC—melanoma	0.00035	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—WNT5A—melanoma	0.00035	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—melanoma	0.000343	0.00124	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EDN1—melanoma	0.000343	0.00124	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CSF2—melanoma	0.000335	0.00121	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—RAC1—melanoma	0.000328	0.00119	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—melanoma	0.000323	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCA—melanoma	0.000321	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAP2K2—melanoma	0.000314	0.00114	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—F2R—melanoma	0.000307	0.00111	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—melanoma	0.000299	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAC1—melanoma	0.000298	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDNRB—melanoma	0.000298	0.00108	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTK2B—melanoma	0.000289	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—melanoma	0.000286	0.00104	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GAB2—melanoma	0.000281	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNA11—melanoma	0.000281	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FLT1—melanoma	0.00028	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—melanoma	0.000277	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCR4—melanoma	0.000264	0.000957	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HDAC2—melanoma	0.000264	0.000957	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FOXO4—melanoma	0.000264	0.000957	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—melanoma	0.000264	0.000957	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNAQ—melanoma	0.000261	0.000947	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—melanoma	0.000252	0.000912	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SYK—melanoma	0.000246	0.00089	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—melanoma	0.000244	0.000883	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NGFR—melanoma	0.000241	0.000874	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT3—melanoma	0.000241	0.000874	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITGAV—melanoma	0.000241	0.000874	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOCS1—melanoma	0.000223	0.000809	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAP2K1—melanoma	0.000223	0.000807	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—S100B—melanoma	0.000223	0.000807	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—melanoma	0.000221	0.000802	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB4—melanoma	0.000213	0.000772	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—melanoma	0.000212	0.00077	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN2B—melanoma	0.000211	0.000765	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CD86—melanoma	0.000204	0.00074	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—melanoma	0.000204	0.00074	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EDN1—melanoma	0.000203	0.000734	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF1—melanoma	0.000198	0.000717	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CSF2—melanoma	0.000198	0.000717	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—melanoma	0.000195	0.000707	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—E2F1—melanoma	0.000194	0.000702	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—melanoma	0.000193	0.000699	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDGFRA—melanoma	0.000192	0.000695	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ITGB3—melanoma	0.00019	0.000688	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCA—melanoma	0.00019	0.000688	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SPP1—melanoma	0.000186	0.000675	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP2K2—melanoma	0.000186	0.000672	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—melanoma	0.000185	0.000672	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—melanoma	0.000177	0.000642	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—melanoma	0.000176	0.000639	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAC1—melanoma	0.000176	0.000638	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—melanoma	0.000169	0.000612	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—melanoma	0.000161	0.000585	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FN1—melanoma	0.000155	0.000563	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH1—melanoma	0.000152	0.000551	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CD80—melanoma	0.000149	0.00054	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—melanoma	0.000149	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KIT—melanoma	0.000149	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—melanoma	0.000149	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NRAS—melanoma	0.000149	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGF—melanoma	0.000147	0.000533	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—melanoma	0.000142	0.000516	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—melanoma	0.00014	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1—melanoma	0.000136	0.000493	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK1—melanoma	0.000135	0.000491	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—melanoma	0.000135	0.000491	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP2K1—melanoma	0.000132	0.000477	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—melanoma	0.000131	0.000474	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—melanoma	0.000129	0.000469	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—melanoma	0.000128	0.000464	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF2—melanoma	0.000125	0.000454	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—melanoma	0.000118	0.000426	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—melanoma	0.000117	0.000424	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—melanoma	0.000115	0.000418	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—melanoma	0.000114	0.000413	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—melanoma	0.000109	0.000397	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—melanoma	0.000109	0.000394	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1B—melanoma	0.000107	0.000387	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—melanoma	0.000106	0.000383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—melanoma	0.000105	0.00038	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—melanoma	0.000105	0.000379	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—melanoma	0.000104	0.000377	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—melanoma	0.000102	0.00037	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CTNNB1—melanoma	0.000101	0.000366	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—melanoma	9.9e-05	0.000359	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—melanoma	9.87e-05	0.000358	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—melanoma	9.84e-05	0.000357	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NFKB1—melanoma	9.8e-05	0.000355	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—melanoma	9.6e-05	0.000348	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—melanoma	8.89e-05	0.000322	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—melanoma	8.8e-05	0.000319	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRAS—melanoma	8.78e-05	0.000318	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—melanoma	8.41e-05	0.000305	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—melanoma	8.18e-05	0.000296	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK1—melanoma	8e-05	0.00029	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—melanoma	8e-05	0.00029	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—melanoma	7.56e-05	0.000274	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—melanoma	6.94e-05	0.000252	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—melanoma	6.72e-05	0.000243	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—melanoma	6.43e-05	0.000233	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—melanoma	6.15e-05	0.000223	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—melanoma	5.67e-05	0.000206	CbGpPWpGaD
